- Home
- MPB vs PRTC Comparison
MPB vs PRTC Comparison
Compare MPB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PRTC
- Stock Information
- Founded
- MPB 1868
- PRTC 2015
- Country
- MPB United States
- PRTC United States
- Employees
- MPB N/A
- PRTC N/A
- Industry
- MPB Major Banks
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PRTC Health Care
- Exchange
- MPB Nasdaq
- PRTC Nasdaq
- Market Cap
- MPB 467.7M
- PRTC 439.8M
- IPO Year
- MPB N/A
- PRTC N/A
- Fundamental
- Price
- MPB $27.00
- PRTC $17.90
- Analyst Decision
- MPB Buy
- PRTC Buy
- Analyst Count
- MPB 2
- PRTC 1
- Target Price
- MPB $36.00
- PRTC $45.00
- AVG Volume (30 Days)
- MPB 67.9K
- PRTC 2.0K
- Earning Date
- MPB 07-23-2025
- PRTC 04-30-2025
- Dividend Yield
- MPB 2.96%
- PRTC N/A
- EPS Growth
- MPB 23.94
- PRTC N/A
- EPS
- MPB 2.88
- PRTC 0.21
- Revenue
- MPB $181,865,000.00
- PRTC $4,828,000.00
- Revenue This Year
- MPB $24.31
- PRTC $35.98
- Revenue Next Year
- MPB $13.74
- PRTC $115.38
- P/E Ratio
- MPB $9.38
- PRTC $7.81
- Revenue Growth
- MPB 9.21
- PRTC 44.98
- 52 Week Low
- MPB $20.03
- PRTC $13.30
- 52 Week High
- MPB $33.87
- PRTC $28.39
- Technical
- Relative Strength Index (RSI)
- MPB 51.24
- PRTC 46.07
- Support Level
- MPB $26.17
- PRTC $19.00
- Resistance Level
- MPB $26.75
- PRTC $19.80
- Average True Range (ATR)
- MPB 0.56
- PRTC 0.33
- MACD
- MPB 0.04
- PRTC -0.12
- Stochastic Oscillator
- MPB 83.69
- PRTC 16.30
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.